Equities

Dynavax Technologies Corp

Dynavax Technologies Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.45
  • Today's Change0.085 / 0.69%
  • Shares traded290.55k
  • 1 Year change-7.68%
  • Beta1.3292
Data delayed at least 15 minutes, as of Nov 22 2024 18:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Dynavax Technologies Corp have a median target of 25.00, with a high estimate of 29.00 and a low estimate of 15.00. The median estimate represents a 102.27% increase from the last price of 12.36.
High134.6%29.00
Med102.3%25.00
Low21.4%15.00

Earnings history & estimates in USD

On Nov 07, 2024, Dynavax Technologies Corp reported 3rd quarter 2024 earnings of 0.12 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 3rd quarter results by 20.00%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-25.00%
Dynavax Technologies Corp reported annual 2023 losses of -0.05 per share on Feb 22, 2024.
Average growth rate+155.45%
More ▼

Revenue history & estimates in USD

Dynavax Technologies Corporation had 3rd quarter 2024 revenues of 80.63m. This missed the 84.17m consensus estimate of the 5 analysts following the company. This was 71.83% above the prior year's 3rd quarter results.
Average growth rate+6.47%
Dynavax Technologies Corporation had revenues for the full year 2023 of 232.28m. This was 67.86% below the prior year's results.
Average growth rate+218.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.